"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 3 | 0 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder. JAMA Psychiatry. 2026 May 01; 83(5):491-498.
-
Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial. Addiction. 2026 Mar; 121(3):629-642.
-
Impact of increased criminal penalties for fentanyl possession on initiation and retention on medications for opioid use disorder in Colorado. Int J Drug Policy. 2025 12; 146:105037.
-
Risk of self-harm and overdose after starting buprenorphine for opioid use disorder. Gen Hosp Psychiatry. 2025 Sep-Oct; 96:90-96.
-
Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 04; 7(11):e2447447.
-
Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder. J Med Internet Res. 2023 06 13; 25:e45556.
-
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings. PLoS One. 2022; 17(10):e0276066.
-
Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV. J Gen Intern Med. 2021 04; 36(4):930-937.
-
Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention. J Subst Abuse Treat. 2021 07; 126:108318.
-
PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021 01 31; 16(1):9.